Anti-interleukin-6
Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers.[1] Hence, anti-IL6 agents have been sought.[2][3][4][5][6] In rheumatoid arthritis they can help patients unresponsive to TNF inhibitors.[7]
The first approved medication in this class,
Tocilizumab was first used in large-cell lung carcinoma. In phase I/II trial of tocilizumab in ovarian cancer EGFR pathway upregulation was observed and after inhibition of this pathway by gefitinib tumor growth was decreased both in vitro and in vivo.[10]
Several agents are in clinical trials:
: Table1e.g. for rheumatoid arthritis : clazakizumab, olokizumab, sarilumab and sirukumab have all reported encouraging phase 2 results.[7] Sirukumab is in multiple phase 3 trials.[7]: Table1
Agents in pre-clinical development include ARGX-109,[15][16] FE301,[1] and FM101.[17]
During the COVID-19 pandemic, antagonistic antibodies against the IL-6 receptors were tested in clinical trials to assess their use in treating or preventing severe pneumonia in critically ill COVID-19 patients. Such antibodies include tocilizumab and sarilumab.[18][19][20] Antibodies against IL-6 itself, such as siltuximab, were also investigated.[21] Also: Levilimab.
Exercise induced IL-6
New research has found IL-6 to be an anti-inflammatory cytokine with multiple beneficial effects when released by contracting muscle as a
IL6 and asthma
Obesity is a known risk factor in the development of severe asthma, and work has suggested that IL-6 plays a role in regulating disease severity in obesity-related asthma.[24]
Luteolin reduces IL-6 production in some neurons.[25]
References
- ^ PMID 21881215.
- S2CID 45421426.
- PMID 16899109.
- .
- ^ "Interleukin-6 – new target in the battle against Ras-induced cancers". 2007.
- S2CID 24296997.
- ^ PMID 24833786.
- PMID 23144446.
- ^ http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf[full citation needed][permanent dead link]
- PMID 26854213.
- ^ FDA Gives Nod to Sarilumab for Rheumatoid Arthritis. 2017
- ^ "UCB Announces Start Of Phase I Study For Antibody Drug Candidate CDP6038". 2 Dec 2008.
- ^ "Article > UCB's RA drug does not overly impress in Phase II". Archived from the original on 2015-12-22. Retrieved 2015-07-26.[full citation needed]
- S2CID 45761175.
- ^ "ArGEN-X Wins €1.5M IWT Grant to Progress Camelid-Derived Human Antibody Pipeline". 27 Sep 2010.
- ^ "RuiYi (Formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody" (Press release).
- ^ "Formatech to Donate Services to Formulate and Fill Femta Pharmaceuticals' FM101 Monoclonal Antibody under Its "Fillanthrop". 30 July 2010.
- ^ "Regeneron, Sanofi Launch Clinical Trial of Kevzara as Coronavirus Treatment". GEN - Genetic Engineering and Biotechnology News. 2020-03-16. Retrieved 2020-04-11.
- ^ "ChinaXiv.org 中国科学院科技论文预发布平台". www.chinaxiv.org. Retrieved 2020-04-11.
- PMID 35315395.
- ^ "EUSA Pharma initiates study of siltuximab to treat Covid-19 patients". Clinical Trials Arena. 2020-03-19. Retrieved 2020-04-11.
- PMID 9130176.
- ^ PMID 23897689.
- PMID 27283230.
- PMID 18490655.